Cerebral Vascular Smooth Muscle Cells plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
Cerebral vascular smooth muscle cells (cVSMCs) are specialized contractile cells that line the walls of cerebral arteries, arterioles, and small arteries within the brain. These cells play essential roles in regulating cerebral blood flow (CBF), maintaining the blood-brain barrier (BBB), and supporting brain homeostasis[1][2]. cVSMC dysfunction is increasingly recognized as a critical contributor to neurodegenerative processes in Alzheimer's disease (AD), Parkinson's disease (PD), vascular dementia, and other neurological disorders[3][4].
| Taxonomy | ID | Name / Label |
|---|---|---|
| Cell Ontology (CL) | CL:0000359 | vascular associated smooth muscle cell |
| Database | ID | Name | Confidence |
|---|---|---|---|
| Cell Ontology | CL:0000359 | vascular associated smooth muscle cell | Medium |
The cerebral vasculature contains approximately 100 billion capillary endothelial cells supported by pericytes and surrounded by astrocyte end-feet, all of which work in concert with cVSMCs to maintain optimal brain function. Unlike peripheral vascular smooth muscle cells, cVSMCs exhibit unique phenotypic characteristics that reflect their specialized role in neural tissue perfusion[1:1]. These cells respond to neural activity through neurovascular coupling, ensuring that energy demands of active neurons are met through increased blood flow.
The importance of cVSMCs in neurodegeneration has become increasingly apparent through research linking vascular risk factors to cognitive decline and demonstrating that cerebrovascular pathology precedes or accompanies hallmark proteinopathies in AD and PD[3:1][4:1]. Understanding cVSMC biology provides crucial insights into disease mechanisms and identifies potential therapeutic targets.
The cerebral arterial tree consists of distinct compartments, each with characteristic cVSMC populations[1:2][2:1]:
cVSMCs exhibit a distinctive contractile phenotype characterized by:
| Protein | Function | Clinical Significance |
|---|---|---|
| α-Smooth Muscle Actin (αSMA) | Contractile apparatus | Marker of differentiation |
| Smooth Muscle Myosin Heavy Chain (SM-MHC) | Force generation | Contractile phenotype marker |
| Calponin | Actin binding | Differentiation marker |
| SM22α | Cytoskeletal organization | Transdifferentiation marker |
| Vimentin | Intermediate filament | Phenotypic switching |
| Desmin | Force transmission | Structural integrity |
cVSMC function depends on precisely regulated ion channel expression[2:3][5]:
Calcium signaling:
Contractile receptors:
Relaxing receptors:
Key intracellular signaling cascades in cVSMCs:
cVSMCs maintain constant CBF across a wide range of systemic blood pressures (approximately 60-150 mmHg mean arterial pressure)[1:3][2:4]:
Activity-dependent blood flow regulation requires cVSMC coordination[1:4][3:2]:
cVSMCs contribute to BBB integrity through[2:5]:
cVSMC dysfunction is central to the neurovascular unit damage seen in Alzheimer's disease, Parkinson's disease, and vascular dementia, interacting with amyloid-beta and tau pathology.
cVSMC dysfunction represents a major contributor to vascular cognitive impairment and interacts with AD pathology[3:3][7]:
Mechanisms:
Cerebral amyloid angiopathy (CAA): Aβ deposition in cVSMC membranes leads to:
Vessel rarefaction: Progressive loss of cerebral vessels reduces CBF
White matter hypoperfusion: Contributing to white matter lesions
Neurovascular uncoupling: Impaired functional hyperemia
Clinical manifestations:
Therapeutic targets:
cVSMC involvement in PD and Lewy body dementia involves alpha-synuclein pathology and neuroinflammation, with parallels to cerebral amyloid angiopathy in AD.
Mechanisms:
Clinical manifestations:
cVSMC dysfunction is central to vascular cognitive impairment[8]:
Notch3 mutations cause hereditary cVSMC degeneration[6:1][9]:
| Drug Class | Mechanism | Clinical Use |
|---|---|---|
| Calcium channel blockers | Reduce Ca²⁺ influx | Nimodipine for subarachnoid hemorrhage |
| ACE inhibitors/ARBs | Reduce Ang II | Blood pressure control |
| Statins | Pleiotropic effects | Atheroprotection |
| PDE5 inhibitors | Enhance cGMP | Experimental for CBF |
| Endothelin antagonists | Block ETA/ETB | Experimental |
Cerebral Vascular Smooth Muscle Cells plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
The study of Cerebral Vascular Smooth Muscle Cells has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Iadecola C, Neurovascular regulation in the normal brain and in AD (2004). 2004. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Rubin LL, The blood-brain barrier (2007). 2007. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Zlokovic BV, Neurovascular pathways to neurodegeneration in AD (2011). 2011. ↩︎ ↩︎ ↩︎ ↩︎
Guajardo-Correa E et al. Cerebrovascular dysfunction in PD (2022). 2022. ↩︎ ↩︎
Brozovich FV et al. Mechanisms of vascular smooth muscle contraction (2016). 2016. ↩︎ ↩︎
Joutel A et al. Notch3 mutations in CADASIL (1996). 1996. ↩︎ ↩︎
Kelley RE, Cerebral amyloid angiopathy in AD (2020). 2020. ↩︎ ↩︎ ↩︎ ↩︎
Gorelick PB et al. Vascular cognitive impairment (2011). 2011. ↩︎
Chabriat H et al. CADASIL (2009). 2009. ↩︎